16
views
0
recommends
+1 Recommend
1 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Serial markers of coagulation and inflammation and the occurrence of clinical pulmonary thromboembolism in mechanically ventilated patients with SARS-CoV-2 infection; the prospective Maastricht intensive care COVID cohort

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Background

          The incidence of pulmonary thromboembolism is high in SARS-CoV-2 patients admitted to the Intensive Care. Elevated biomarkers of coagulation (fibrinogen and D-dimer) and inflammation (c-reactive protein (CRP) and ferritin) are associated with poor outcome in SARS-CoV-2. Whether the time-course of fibrinogen, D-dimer, CRP and ferritin is associated with the occurrence of pulmonary thromboembolism in SARS-CoV-2 patients is unknown. We hypothesise that patients on mechanical ventilation with SARS-CoV-2 infection and clinical pulmonary thromboembolism have lower concentrations of fibrinogen and higher D-dimer, CRP, and ferritin concentrations over time compared to patients without a clinical pulmonary thromboembolism.

          Methods

          In a prospective study, fibrinogen, D-dimer, CRP and ferritin were measured daily. Clinical suspected pulmonary thromboembolism was either confirmed or excluded based on computed tomography pulmonary angiography (CTPA) or by transthoracic ultrasound (TTU) (i.e., right-sided cardiac thrombus). In addition, patients who received therapy with recombinant tissue plasminogen activator were included when clinical instability in suspected pulmonary thromboembolism did not allow CTPA. Serial data were analysed using a mixed-effects linear regression model, and models were adjusted for known risk factors (age, sex, APACHE-II score, body mass index), biomarkers of coagulation and inflammation, and anticoagulants.

          Results

          Thirty-one patients were considered to suffer from pulmonary thromboembolism ((positive CTPA ( n = 27), TTU positive ( n = 1), therapy with recombinant tissue plasminogen activator ( n = 3)), and eight patients with negative CTPA were included. After adjustment for known risk factors and anticoagulants, patients with, compared to those without, clinical pulmonary thromboembolism had lower average fibrinogen concentration of − 0.9 g/L (95% CI: − 1.6 – − 0.1) and lower average ferritin concentration of − 1045 μg/L (95% CI: − 1983 – − 106) over time. D-dimer and CRP average concentration did not significantly differ, 561 μg/L (− 6212–7334) and 27 mg/L (− 32–86) respectively. Ferritin lost statistical significance, both in sensitivity analysis and after adjustment for fibrinogen and D-dimer.

          Conclusion

          Lower average concentrations of fibrinogen over time were associated with the presence of clinical pulmonary thromboembolism in patients at the Intensive Care, whereas D-dimer, CRP and ferritin were not. Lower concentrations over time may indicate the consumption of fibrinogen related to thrombus formation in the pulmonary vessels.

          Supplementary Information

          The online version contains supplementary material available at 10.1186/s12959-021-00286-7.

          Related collections

          Most cited references64

          • Record: found
          • Abstract: found
          • Article: found

          Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia

          Abstract Background In the recent outbreak of novel coronavirus infection in Wuhan, China, significantly abnormal coagulation parameters in severe novel coronavirus pneumonia (NCP) cases were a concern. Objectives To describe the coagulation feature of patients with NCP. Methods Conventional coagulation results and outcomes of 183 consecutive patients with confirmed NCP in Tongji hospital were retrospectively analyzed. Results The overall mortality was 11.5%, the non‐survivors revealed significantly higher D‐dimer and fibrin degradation product (FDP) levels, longer prothrombin time and activated partial thromboplastin time compared to survivors on admission (P < .05); 71.4% of non‐survivors and 0.6% survivors met the criteria of disseminated intravascular coagulation during their hospital stay. Conclusions The present study shows that abnormal coagulation results, especially markedly elevated D‐dimer and FDP are common in deaths with NCP.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            High risk of thrombosis in patients with severe SARS-CoV-2 infection: a multicenter prospective cohort study

            Little evidence of increased thrombotic risk is available in COVID-19 patients. Our purpose was to assess thrombotic risk in severe forms of SARS-CoV-2 infection.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              COVID-19 and its implications for thrombosis and anticoagulation

              Severe acute respiratory syndrome coronavirus 2, coronavirus disease 2019 (COVID-19)-induced infection can be associated with a coagulopathy, findings consistent with infection-induced inflammatory changes as observed in patients with disseminated intravascular coagulopathy (DIC). The lack of prior immunity to COVID-19 has resulted in large numbers of infected patients across the globe and uncertainty regarding management of the complications that arise in the course of this viral illness. The lungs are the target organ for COVID-19; patients develop acute lung injury that can progress to respiratory failure, although multiorgan failure can also occur. The initial coagulopathy of COVID-19 presents with prominent elevation of D-dimer and fibrin/fibrinogen-degradation products, whereas abnormalities in prothrombin time, partial thromboplastin time, and platelet counts are relatively uncommon in initial presentations. Coagulation test screening, including the measurement of D-dimer and fibrinogen levels, is suggested. COVID-19–associated coagulopathy should be managed as it would be for any critically ill patient, following the established practice of using thromboembolic prophylaxis for critically ill hospitalized patients, and standard supportive care measures for those with sepsis-induced coagulopathy or DIC. Although D-dimer, sepsis physiology, and consumptive coagulopathy are indicators of mortality, current data do not suggest the use of full-intensity anticoagulation doses unless otherwise clinically indicated. Even though there is an associated coagulopathy with COVID-19, bleeding manifestations, even in those with DIC, have not been reported. If bleeding does occur, standard guidelines for the management of DIC and bleeding should be followed.
                Bookmark

                Author and article information

                Contributors
                mark.mulder@mumc.nl
                lloyd.brandts@mumc.nl
                renee.bruggemann@mumc.nl
                m.koelmann@student.maastrichtuniversity.nl
                sander.streng@mumc.nl
                renske.olie@mumc.nl
                hester.gietema@mumc.nl
                henri.spronk@maastrichtuniversity.nl
                iwan.vander.horst@mumc.nl
                janwillem.sels@mumc.nl
                j.wildberger@mumc.nl
                sander.van.kuijk@mumc.nl
                r.schnabel@mumc.nl
                h.ten.cate@mumc.nl
                yvonne.henskens@mumc.nl
                bas.van.bussel@mumc.nl
                Journal
                Thromb J
                Thromb J
                Thrombosis Journal
                BioMed Central (London )
                1477-9560
                31 May 2021
                31 May 2021
                2021
                : 19
                : 35
                Affiliations
                [1 ]GRID grid.412966.e, ISNI 0000 0004 0480 1382, Department of Intensive Care Medicine, , Maastricht University Medical Centre+, ; Maastricht, The Netherlands
                [2 ]GRID grid.412966.e, ISNI 0000 0004 0480 1382, Department of Clinical Epidemiology and Medical Technology Assessment, , Maastricht University Medical Centre+, ; Maastricht, The Netherlands
                [3 ]GRID grid.412966.e, ISNI 0000 0004 0480 1382, Department of Internal Medicine, , Maastricht University Medical Centre+, ; Maastricht, The Netherlands
                [4 ]GRID grid.412966.e, ISNI 0000 0004 0480 1382, Department of Clinical Chemistry, Central Diagnostic Laboratory, , Maastricht University Medical Centre+, ; Maastricht, The Netherlands
                [5 ]GRID grid.412966.e, ISNI 0000 0004 0480 1382, Thrombosis Expert Centre Maastricht and Department of Internal Medicine, Section Vascular Medicine, , Maastricht University Medical Centre+, ; Maastricht, The Netherlands
                [6 ]GRID grid.5012.6, ISNI 0000 0001 0481 6099, Cardiovascular Research Institute Maastricht (CARIM), , Maastricht University, ; Maastricht, The Netherlands
                [7 ]GRID grid.412966.e, ISNI 0000 0004 0480 1382, Department of Radiology and Nuclear Medicine, , Maastricht University Medical Centre+, ; Maastricht, The Netherlands
                [8 ]GRID grid.5012.6, ISNI 0000 0001 0481 6099, GROW School of Oncology and Developmental Biology, , Maastricht University, ; Maastricht, The Netherlands
                [9 ]GRID grid.412966.e, ISNI 0000 0004 0480 1382, Department of Cardiology, , Maastricht University Medical Centre+, ; Maastricht, The Netherlands
                [10 ]GRID grid.412966.e, ISNI 0000 0004 0480 1382, Care and Public Health Research Institute, , Maastricht University Medical Centre+, ; Maastricht, The Netherlands
                Author information
                http://orcid.org/0000-0002-6485-8060
                https://orcid.org/0000-0002-0620-1271
                https://orcid.org/0000-0003-1482-4708
                https://orcid.org/0000-0002-4710-9236
                https://orcid.org/0000-0001-6077-1446
                https://orcid.org/0000-0002-3858-334X
                https://orcid.org/0000-0003-3891-8522
                https://orcid.org/0000-0002-4810-6854
                https://orcid.org/0000-0003-2796-729X
                https://orcid.org/0000-0001-8410-332X
                https://orcid.org/0000-0001-7796-4463
                https://orcid.org/0000-0003-1621-7848
                Article
                286
                10.1186/s12959-021-00286-7
                8165953
                34059058
                a3f19c45-9835-4548-82ed-bac85ae5bca4
                © The Author(s) 2021

                Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver ( http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

                History
                : 25 February 2021
                : 7 May 2021
                Categories
                Research
                Custom metadata
                © The Author(s) 2021

                Cardiovascular Medicine
                sars-cov-2,covid-19,pulmonary embolism,pulmonary thrombosis,coagulation,d-dimer,fibrinogen,c-reactive protein,intensive care

                Comments

                Comment on this article